Apparatus

Accelerating and simplifying the development and manufacturing process of cell and gene therapies.

Recently, a study for the treatment of advanced EGFR-mutated and c-MET-positive lung cancer showed good results with the cutting-edge ADC drug teliso-V in combination with the EGFR generation-targeted drug troche (i.e. erlotinib).

Recently, the frontier drug INT230-6 showed good tumour killing effects in the treatment of soft tissue sarcoma in the single arm phase 1/2 open-label clinical trial IT-01 (NCT03058289), and the drug showed good responses whether injected inside the tumour alone or in combination with the CTLA-4 immune checkpoint inhibitor ipilimumab.

Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.

Eisai and Biogen have partnered to develop Leqembi and have priced it at $26,500 per year.

The "me better" strategy has always been a great story for pharmaceutical companies.

The dental profession can use these tools as a guide to improve the sustainability of their working environment and to recognise their efforts by tracking progress.

According to Telegraph, a new study shows that human doctors will still outperform "robot doctors" in surgery. Compared with robots, human doctors need shorter time to complete surgery, and the error rate is not high.

The results of a new study recently showed that Olutasidenib monotherapy in patients with relapsed/refractory acute myeloid leukaemia carrying the IDH1 mutation elicited high rates of complete remission with manageable toxicity.

The collaboration aims to improve the efficiency of the drug discovery pipeline by leveraging industry-leading capabilities to identify genetic variants that cause human disease.